Mercury Bio Appoints Casey Perkins to Enhance CNS Therapeutics Leadership and Strategy

Mercury Bio Strengthens Leadership with Strategic Appointment in CNS Therapeutics

Mercury Bio, a leader in enhancing intracellular delivery for central nervous system (CNS) therapeutics, appoints Cassandra "Casey" Perkins as Vice President of Corporate Strategy & Business Development. With an extensive background spanning over 25 years in the biotech and pharmaceutical sectors, Perkins brings a wealth of knowledge in commercial strategy and market access, particularly focused on rare diseases and advanced therapies. Her previous experience includes key roles in the commercialization of groundbreaking treatments such as ZOLGENSMA®, where she honed her skills in building patient-centered access models and strategic growth frameworks. This significant appointment signals Mercury Bio’s commitment to advancing its innovative yEV™ drug delivery platform, which aims to revolutionize the treatment landscape for neurological disorders.

In her new role, Perkins will spearhead corporate strategy and business development efforts, concentrating on forming strategic partnerships and fostering investor relations. The yEV™ platform, which employs yeast-derived exosomes to deliver therapeutic proteins, RNA, and other molecular agents, has recently shown promising results in pre-clinical studies. These studies demonstrated the successful delivery of nanobodies across the blood-brain barrier in murine models, pointing to the platform's potential to develop new therapies for conditions like Alzheimer's and Parkinson's diseases. Perkins will collaborate closely with key executives, including Chief Scientific Officer Richard Sayre, Ph.D., and CEO Bruce McCormick, to showcase these advancements at the upcoming Biotech Showcase in San Francisco, where the company aims to highlight the capabilities of its innovative platform.

Mercury Bio considers Perkins’ leadership essential as it navigates the complexities of the biotechnology landscape. As the company seeks to expand its therapeutic pipeline and enhance its market presence, Perkins’ expertise in developing strategic partnerships will likely play a crucial role in propelling the company’s mission forward. Her appointment is seen as a pivotal moment for Mercury Bio, which is keen to capitalize on its recent breakthroughs and solidify its position in the CNS therapeutics arena.

In a related note, Mercury Bio's advancements in drug delivery technology underscore the growing interest in addressing complex neurological disorders through innovative solutions. As the company prepares for its presentation at the Biotech Showcase, it aims to attract potential collaborators and investors who share its vision for harnessing cutting-edge technologies to transform patient outcomes. The developments surrounding the yEV™ platform reflect the increasing importance of strategic leadership and partnerships in the fast-evolving biotech industry.